Open Access
CC BY 4.0 · Arch Plast Surg 2023; 50(05): 478-487
DOI: 10.1055/a-2113-3084
Pediatric/Craniomaxillofacial/Head & Neck
Original Article

Consequence of Synthetic Bone Substitute Used for Alveolar Cleft Graft Reconstruction (Preliminary Clinical Study)

Rawaa Y. Al-Rawee
1   Department of Oral and Maxillofacial Surgery, Al-Salam Teaching Hospital. Mosul, Iraq
,
4   Department of Oral and Maxillofacial Surgery, Al-Noor University College, Mosul, Iraq
,
3   Department of Pediatric Surgery, Al-Khansa Teaching Hospital, Mosul, Iraq
,
2   Paedo Ortho Prevention Department, Alnoor University College, Mosul, Iraq
› Author Affiliations

Funding None.
Preview

Abstract

Background The outcome of alveolar grafting with synthetic bone substitute (Osteon III) in various bone defect volumes is highlighted.

Methods A prospective study was accomplished on 55 patients (6–13 years of age) with unilateral alveolar bone cleft. Osteon III, consisting of hydroxyapatite and tricalcium phosphate, is used to reconstruct the defect. Alveolus defect diameter was calculated before surgery (V1), after 3 months (V2), and finally after 6 months (V3) postsurgery. In the t-test, a significant difference and correlation between V1, V2, and V3 are stated. A p-value of 0.01 is considered a significant difference between parameters.

Results The degree of cleft is divided into three categories: small (9 cases), medium (20 patients), and large (26 cases).The bone volume of the clefted site is divided into three steps: volume 1: (mean 18.1091 mm3); step 2: after 3 months, volume 2 resembles the amount of unhealed defect (mean 0.5109 mm3); and the final bone volume assessment is made after 6 months (22.5455 mm3). Both show statistically significant differences in bone volume formation.

Conclusion An alloplastic bone substitute can also be used as a graft material because of its unlimited bone retrieval. Osteon III can be used to reconstruct the alveolar cleft smoothly and effectively.

Authors' Contributions

R.Y.Al-R. conceived the ideas, led the writing, and collected the data. A.M.H. analyzed the data; and B.A.-G.T. Z.S.T collected the data with coordination with A.M.H. and approved the writing scientifically.


Ethical Approval

The study ethically approved by the Human Ethical Scientific Approval Application Form for Research of the Nineveh Health Directory, Ministry of Health, Iraq with licensed number 67/120.


Patient Consent

Authors can confirm that written informed consent obtained from study participants and clearly stated this in the manuscript.




Publication History

Received: 28 April 2022

Accepted: 15 June 2023

Accepted Manuscript online:
20 June 2023

Article published online:
31 August 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA